M-ZOLE 7 DUAL PACK

Post-LOE

miconazole nitrate

Teva

ANDATOPICAL, VAGINALCREAM, SUPPOSITORY

Approved

Jul 1997

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

M-ZOLE 7 DUAL PACK (miconazole nitrate) by Teva is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida. First approved in 1997.

Drug data last refreshed 1w ago

Mechanism of Action

CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (1)

NCT00702507Phase 4Completed

Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants

Started May 2007

200 enrolled

Diaper Rash

Worked on M-ZOLE 7 DUAL PACK at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.